Related references
Note: Only part of the references are listed.Spitz Tumors With ROS1 Fusions: A Clinicopathological Study of 6 Cases, Including FISH for Chromosomal Copy Number Alterations and Mutation Analysis Using Next-Generation Sequencing
Michele Donati et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2020)
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)
Rita Chiari et al.
CLINICAL LUNG CANCER (2020)
Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization
Richard S. P. Huang et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions
Hiroki Sato et al.
CLINICAL CANCER RESEARCH (2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon et al.
NATURE MEDICINE (2020)
Characterization of on-target adverse events caused by TRK inhibitor therapy
D. Liu et al.
ANNALS OF ONCOLOGY (2020)
Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.
Jessica Jiyeong Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab
Yuling Zhou et al.
LUNG CANCER (2020)
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer
Marliese Alexander et al.
LUNG CANCER (2020)
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants
Haiyan Xu et al.
CANCER MEDICINE (2020)
First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer
Lan Shen et al.
CANCER MEDICINE (2020)
NELL2-mediated lumicrine signaling through OVCH2 is required for male fertility
Daiji Kiyozumi et al.
SCIENCE (2020)
Characteristics of Patients With ROS1+ Cancers: Results From the First Patient-Designed, Global, Pan-Cancer ROS1 Data Repository
Divya A. Parikh et al.
JCO ONCOLOGY PRACTICE (2020)
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer
Thomas Yang Sun et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis
Tamio Okimoto et al.
INTERNAL MEDICINE (2019)
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC
Ibiayi Dagogo-Jack et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Clinical Management of Adverse Events Associated with Lorlatinib
Todd M. Bauer et al.
ONCOLOGIST (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed et al.
CLINICAL CANCER RESEARCH (2019)
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Giles W. Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients
Veronique Hofman et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
Sebastian Michels et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
CNS metastasis in ROS1 + NSCLC: An urgent call to action, to understand, and to overcome
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2019)
Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer in Routine Clinical Practice
Chang Liu et al.
TARGETED ONCOLOGY (2019)
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study
Esther Conde et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Gene expression across mammalian organ development
Margarida Cardoso-Moreira et al.
NATURE (2019)
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Lorenza Landi et al.
CLINICAL CANCER RESEARCH (2019)
Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors
Carina Heydt et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Emiliano Cocco et al.
NATURE MEDICINE (2019)
Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
Yueming He et al.
ONCOLOGY RESEARCH (2019)
444PDSafety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
A Drilon et al.
ANNALS OF ONCOLOGY (2019)
LBA28Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2
R C Doebele et al.
ANNALS OF ONCOLOGY (2019)
GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors
Timothy E. Richardson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2019)
Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
Ana S. Guerreiro Stucklin et al.
NATURE COMMUNICATIONS (2019)
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Dana S. Neel et al.
CANCER RESEARCH (2019)
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors
David S. Hong et al.
CLINICAL CANCER RESEARCH (2019)
Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion
Yong Li et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2019)
Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer
Nick Pavlakis et al.
PATHOLOGY (2019)
Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations
Benjamin M. Parsons et al.
CANCER RESEARCH (2019)
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
Alexander Drilon et al.
CANCER RESEARCH (2019)
Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations
Alexander Drilon et al.
CANCER RESEARCH (2019)
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer
Viola W. Zhu et al.
TRENDS IN CANCER (2019)
CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing
You-cai Zhu et al.
THORACIC CANCER (2018)
A patient with classic biphasic pulmonary blastoma harboring CD74-ROS/fusion responds to crizotinib
Zhaoting Meng et al.
ONCOTARGETS AND THERAPY (2018)
Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
You-cai Zhu et al.
THORACIC CANCER (2018)
CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib
Wenfeng Gou et al.
CANCER LETTERS (2018)
Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature
Benedetta Pellegrino et al.
CLINICAL LUNG CANCER (2018)
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion
Junko Watanabe et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)
David R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer
Ziming Li et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples
Kurtis D. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
Tejas Patil et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Sehhoon Park et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
An anatomic transcriptional atlas of human glioblastoma
Ralph B. Puchalski et al.
SCIENCE (2018)
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer
Ilirjana Bajrami et al.
CANCER DISCOVERY (2018)
Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study
Yutaka Fujiwara et al.
Oncotarget (2018)
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study
S. Gadgeel et al.
ANNALS OF ONCOLOGY (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma
Monika A. Davare et al.
CLINICAL CANCER RESEARCH (2018)
Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions
Srikanth R. Ambati et al.
JCO PRECISION ONCOLOGY (2018)
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer
Curtis R. Chong et al.
CLINICAL CANCER RESEARCH (2017)
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement
Sun Min Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma
Deepa Rangachari et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer
Marcel Wiesweg et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Alison M. Schram et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis
C-H Shih et al.
ONCOGENE (2017)
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
Adrienne Johnson et al.
ONCOLOGIST (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma
Maria Rossing et al.
CANCER GENETICS (2017)
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
Liyan Jiang et al.
ONCOTARGET (2017)
Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma
Sun Min Lim et al.
CANCER RESEARCH AND TREATMENT (2017)
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Aria Vaishnavi et al.
CANCER RESEARCH (2017)
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Alexander Drilon et al.
CLINICAL CANCER RESEARCH (2016)
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini et al.
CLINICAL CANCER RESEARCH (2016)
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency
Maki Inoue et al.
CARCINOGENESIS (2016)
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Francesco Facchinetti et al.
CLINICAL CANCER RESEARCH (2016)
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Sen Zhang et al.
CLINICAL CANCER RESEARCH (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Efficacy of of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations
Yen-Fu Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Scott N. Gettinger et al.
LANCET ONCOLOGY (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
Limin Zhang et al.
ONCOTARGET (2016)
Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy
Zhengbo Song et al.
CANCER MEDICINE (2016)
Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement
Cristina R. Antonescu et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma
Ramona Crescenzo et al.
CANCER CELL (2015)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
Ahnah Song et al.
CLINICAL CANCER RESEARCH (2015)
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Alexander Drilon et al.
CLINICAL CANCER RESEARCH (2015)
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2015)
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Helen Y. Zou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
Monika A. Davare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Crizotinib Reduces the Rate of Dark Adaptation in the Rat Retina Independent of ALK Inhibition
Chang-Ning Liu et al.
TOXICOLOGICAL SCIENCES (2015)
ROS1 Signaling Regulates Epithelial Differentiation in the Epididymis
Hyun Jung Jun et al.
ENDOCRINOLOGY (2014)
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features
Yunjian Pan et al.
LUNG CANCER (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
Thomas Wiesner et al.
NATURE COMMUNICATIONS (2014)
Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Christine M. Lovly et al.
CANCER DISCOVERY (2014)
ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas
Lynette M. Sholl et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
H. R. Kim et al.
ANNALS OF ONCOLOGY (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Ins and Outs of Kinase DFG Motifs
Daniel K. Treiber et al.
CHEMISTRY & BIOLOGY (2013)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
The Genotype-Tissue Expression (GTEx) project
John Lonsdale et al.
NATURE GENETICS (2013)
Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1
Mark M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target
Anna Saborowski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
Monika A. Davare et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
A Correction to the Research Article Titled: "Inositol Polyphosphate Multikinase Is a Coactivator of p53-Mediated Transcription and Cell Death" by R. Xu, N. Sen, B. D. Paul, A. M. Snowman, F. Rao, M. S. Vandiver, J. Xu, S. H. Snyder
Science Signaling (2013)
Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
Andrew J. Weickhardt et al.
CANCER (2012)
The Oncogenic Lung Cancer Fusion Kinase CD74-ROS Activates a Novel Invasiveness Pathway through E-Syt1 Phosphorylation
Hyun Jung Jun et al.
CANCER RESEARCH (2012)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2012)
Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion
Victoria M. Rimkunas et al.
CLINICAL CANCER RESEARCH (2012)
The transcriptional landscape and mutational profile of lung adenocarcinoma
Jeong-Sun Seo et al.
GENOME RESEARCH (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
Hiroyuki Yasuda et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly et al.
CANCER RESEARCH (2011)
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice
Al Charest et al.
CANCER RESEARCH (2006)
Comparison of gene expression and DNA copy number changes in a murine model of lung cancer
A Sweet-Cordero et al.
GENES CHROMOSOMES & CANCER (2006)
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis
A Sweet-Cordero et al.
NATURE GENETICS (2005)
Mouse models of infertility due to swollen spermatozoa
TG Cooper et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2004)
Gene and protein expression in the epididymis of infertile c-ros receptor tyrosine kinase-deficient mice
TG Cooper et al.
BIOLOGY OF REPRODUCTION (2003)
Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas
M Wahrenbrock et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)
A Charest et al.
GENES CHROMOSOMES & CANCER (2003)
Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma
A Charest et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The role of phosphatidylinositol 3-kinase, Rho family GTPases, and STAT3 in Ros-induced cell transformation
KT Nguyen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Negative regulation of Ros receptor tyrosine kinase signaling:: An epithelial function of the SH2 domain protein tyrosine phosphatase SHP-1
H Keilhack et al.
JOURNAL OF CELL BIOLOGY (2001)
Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation
LY Zeng et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
The cause of infertility of male c-ros tyrosine kinase receptor knockout mice
CH Yeung et al.
BIOLOGY OF REPRODUCTION (2000)
Share Paper
